Evidence map›Paper›PMID 33199860›Full record

ReviewNature materials2021

Rethinking organoid technology through bioengineering.

Elena Garreta, Roger D Kamm, Susana M Chuva de Sousa Lopes, Madeline A Lancaster, Ron Weiss, Xavier Trepat, Insoo Hyun, Nuria Montserrat

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature materials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 182 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
182citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

182 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Organoid technology in cancer research.Molecular biomedicine · 2026
    Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

122 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Elena Garreta *Pluripotency for Organ Regeneration, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
Roger D Kamm *Department of Biological Engineering and Department of Mechanical Engineering, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-7232-304X
Susana M Chuva de Sousa LopesDepartment of Anatomy and Embryology, Leiden University Medical Center, Leiden, the Netherlands.ORCID http://orcid.org/0000-0003-3866-2803
Madeline A LancasterMRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Cambridge, UK.ORCID http://orcid.org/0000-0003-2324-8853
Ron WeissDepartment of Biological Engineering, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-0396-2443
Xavier TrepatCentro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina, Barcelona, Spain.
Insoo HyunDepartment of Bioethics, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Nuria MontserratPluripotency for Organ Regeneration, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain. nmontserrat@ibecbarcelona.eu.ORCID http://orcid.org/0000-0002-1603-1755

Funding

Synthetic Genetic Controller Circuits to Reprogram Cell FateR01EB024591 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI COLLINS, JAMES J, DEL VECCHIO, DOMITILLA · 2017 to 2020
$2.5M
Programmed Differentiation Circuits for Organoids using Meso-MicrofluidicsR01EB025256 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI CARR, PETER ANDREW · 2018 to 2021
$2.4M
Medical Research Council MC_UP_1201/9NIBIB NIH HHS R01 EB024591NIBIB NIH HHS R01 EB025256
6 · The paper itself

Abstract

In recent years considerable progress has been made in the development of faithful procedures for the differentiation of human pluripotent stem cells (hPSCs). An important step in this direction has also been the derivation of organoids. This technology generally relies on traditional three-dimensional culture techniques that exploit cell-autonomous self-organization responses of hPSCs with minimal control over the external inputs supplied to the system. The convergence of stem cell biology and bioengineering offers the possibility to provide these stimuli in a controlled fashion, resulting in the development of naturally inspired approaches to overcome major limitations of this nascent technology. Based on the current developments, we emphasize the achievements and ongoing challenges of bringing together hPSC organoid differentiation, bioengineering and ethics. This Review underlines the need for providing engineering solutions to gain control of self-organization and functionality of hPSC-derived organoids. We expect that this knowledge will guide the community to generate higher-grade hPSC-derived organoids for further applications in developmental biology, drug screening, disease modelling and personalized medicine.

Indexed as

BioengineeringHumansOrganoidsPluripotent Stem Cells

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.